Skip to main content

The medicines business | A question to investigate

Access is a decision. Adoption is a journey.

A positive national decision does not tell an industry team exactly how local implementation will unfold. The remaining questions may concern workforce, pathway design, procurement, diagnostics or the capacity to follow people up. NEUVIOR is interested in the gap between an access proposition and the practical work needed in a specific setting. That gap deserves its own evidence, rather than being hidden inside a national opportunity estimate.

Film credits

In the conversation.

NEUVIOR and our founder’s perspectives have appeared across science, business and technology publications.

University of Warwick IATL | AI Ethics NowpharmaphorumTechRadar ProET PharmaFinancial TimesPharmaceutical TechnologyPharmaTimesManufacturing ChemistDigital HealthDaily BusinessTheBusinessDesk.comStartups MagazineInsider MediaYorkshire PostYork PressBusinessCloud

Reporting, commentary, letters and podcast appearances | Read each feature for its format and source.

Describe the work behind the opportunity

An access team may know the eligible population yet have limited evidence about the operational pathway. A provider may understand the pathway but face competing service priorities. A commercial forecast can overlook both perspectives if it assumes eligibility translates directly into adoption. A proposed review would make the implementation sequence visible: what changes, who needs to agree, which resources are required and what evidence would justify the next step in that local context.

Keep national and local evidence separate

NHS England’s medicines procurement function concerns hospital commercial arrangements and supply-chain management (NHS England, n.d.). NHSBSA publishes hospital and community prescribing-cost statistics with defined coverage (NHSBSA, n.d.). These sources can inform a discussion, but neither establishes a particular provider’s capacity or willingness to implement a medicine. Our proposed analysis would distinguish published context from local assumptions and avoid presenting national expenditure as the revenue available to a single supplier.

Understand the incentives around the table

A hospital pharmacy team may need reliable delivery and a workable preparation process. A clinical service may need appointment capacity or monitoring arrangements. A finance team may need the timing of costs and contractual consequences. Industry needs to understand which barrier it can appropriately help address. A useful brief describes these perspectives without assuming that every barrier should be solved by a supplier-funded intervention or that commercial access creates authority over clinical decisions.

An implementation proposition with conditions

A useful output would describe the local delivery conditions under which the proposition could be explored, alongside the facts that remain unconfirmed. It would identify the next appropriate discussion and its purpose. The result should help an industry team approach a provider with a specific, evidence-aware question rather than a national forecast presented as a local opportunity.

A public decision brief | An illustrative example

Open the question.
Inspect the reasoning.

Choose a business question, then look beneath its claim. See what a public source supports, what depends on the local setting and what a useful next step could be.

A medicines or implementation team considering an AI-supported evidence review.

Would a quicker review make the decision better?

The interesting question is the complete piece of work: finding relevant material, checking it, correcting the draft and reaching an accountable decision.

A proposition to investigate

Less preparation. The same ability to challenge.

An evidence-review approach could be useful if it reduces avoidable preparation while preserving source access, relevant qualifications and professional checking. That is the proposed value to test. No time reduction, accuracy improvement or customer result is asserted in this example.

The proposition is constructed for this public brief. It is not a published finding about PHARMORIS.

What the next brief would contain

A decision someone
can commission.

The decision
Whether one defined review task merits an agreed evaluation.
The comparator
The team's existing complete review process, including checking and corrections.
The evidence
Representative cases, source records, reviewer decisions, complete-task effort and exceptions.
Stop or redesign
Stop or redesign if source checking weakens, errors are unacceptable or the complete task offers insufficient value.

Constructed public example | Not PHARMORIS-generated software output or a measured customer result.

Keep this example brief

Start with one pathway question

A bounded PHARMORIS evaluation could examine a permitted, non-promotional implementation question in one care setting. Inputs might include published guidance, approved pathway descriptions, aggregate service activity and locally confirmed resource assumptions. The comparator would be the existing implementation or access brief. The evaluation would test whether dependencies and uncertainties are clearer, not recommend treatment for individuals or claim a provider has agreed to participate before that agreement exists.

Measure readiness with care

Candidate measures include the completeness of the dependency map, the number of assumptions confirmed or rejected by accountable local reviewers, and the work needed to prepare a decision discussion. These measures concern preparation. They do not demonstrate uptake, clinical benefit or financial return. If a later implementation study is justified, its design should distinguish eligibility, actual access, treatment initiation and sustained delivery, with suitable governance and appropriate outcome definitions.

Avoid a forecast that manufactures certainty

We would pause if available data cannot support the population or pathway being discussed, if local reviewers are absent, or if the output is expected to imply endorsement. A sensitivity analysis should show how different capacity and timing assumptions change the proposition. Where a single missing resource determines feasibility, the next step may be a service discussion rather than a more elaborate commercial model. That is a useful finding, not a failed marketing exercise.

A worthwhile industry discussion

Bring one access question where the national case is clearer than the local implementation route. Explain whose decision is needed, what the current evidence says and which dependency remains unresolved. We can explore whether a bounded review could make the conversation more useful for both industry and the health system. The commercial incentive is an implementation proposition grounded in the realities of delivery, with evidence that can be questioned before resources are committed.

Sources and scope

NHS England | Medicines procurement and supply chain | NHSBSA | Hospital and community prescribing costs

Discuss an implementation evidence question

NHS England (n.d.) Medicines procurement and supply chain. Available at: https://www.england.nhs.uk/medicines-2/medicines-value-and-access/medicines-procurement-and-supply-chain/ (Accessed: 14 October 2026).

NHSBSA (n.d.) Hospital and community prescribing costs. Available at: https://www.nhsbsa.nhs.uk/statistical-collections/prescribing-costs-hospitals-and-community-england/prescribing-costs-hospitals-and-community-england-2020-2025 (Accessed: 14 October 2026).

Another useful angle.

NEWSPerspectives & features
Open newsroom